Summary
Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K on June 8, 2017, detailing the outcomes of its 2017 annual shareholder meeting. The key events include the approval of an amendment and restatement of the 2013 Stock and Option Plan, which increases the authorized shares for issuance by 6,750,000. This move is important for potential future equity compensation and employee incentives. Additionally, shareholders elected three directors to the board and approved several other significant proposals. These include amendments to the company's Articles of Organization and By-Laws, ratification of the appointment of Ernst & Young LLP as the independent auditor, and an advisory vote on executive compensation which will now be held annually. A shareholder proposal to eliminate supermajority provisions was also approved, indicating a move towards more straightforward governance.
Key Highlights
- 1Shareholders approved amendments to the 2013 Stock and Option Plan, increasing the share pool by 6,750,000 for future equity awards.
- 2Alan Garber, Margaret G. McGlynn, and William D. Young were elected to the Board of Directors.
- 3Amendments to the company's Articles of Organization and By-Laws were approved.
- 4Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2017.
- 5An advisory vote on executive compensation was approved and will be held annually going forward.
- 6A shareholder proposal to eliminate supermajority provisions in the Articles of Organization and By-Laws was approved.